i
Important informations
Instagram
Portal
Donate now

Our researchers

Aucun résultat

Dr. Stephanie M. Wong

Stephanie M. Wong, MD, MPH

Cancer

Atypical ductal hyperplasia, Atypical lobular hyperplasia, BRCA 1/2, Breast cancer susceptibility genes, Chemoprevention, Endocrine prevention, Lobular carcinoma in situ, Mainstream genetic testing, Prophylactic mastectomy, Risk reducing mastectomy
  • Principal Investigator, Lady Davis Institute for Medical Research
  • Attending Surgeon, Department of Surgery, Jewish General Hospital
  • Assistant Professor, Department of Surgery and Oncology, McGill University
  • Director, JGH Stroll Cancer Prevention Centre High Risk Breast Clinic. Jewish General Hospital

Contact details

sm.wong@mcgill.ca
@stephaniemwong

Assistant contact details

  • Victor Villareal-Corpuz, RN/inf., BNI,
    Clinical Research Coordinator
    (514) 340-8222 ext. 28775
    victor.villareal-corpuz.ccomtl@ssss.gouv.qc.ca

Snapshot

Dr. Stephanie M. Wong’s laboratory explores clinical outcomes and prevention strategies for women at increased breast cancer risk. Her research focuses primarily on patients with inherited susceptibility due to germline pathogenic variants in BRCA1/2, PALB2, ATM, CHEK2 and other genes, as well as those with a history of atypical breast biopsies or a personal history of chest wall radiation therapy in adolescence and young adulthood. For these high risk groups, her research explores uptake and decision making around endocrine prevention and risk reducing mastectomy. She is also involved in initiatives around mainstream genetic testing for patients with newly diagnosed breast cancer.

Important Links :

See Dr. Stephanie M. Wong's publications on PubMed

Major Research Activities

Dr. Stephanie M. Wong’s  research focusses on surgical decision making and prevention strategies in high-penetrance germline pathogenic variant carriers, including in BRCA1/2, PALB2, CDH1, TP53 and PTEN genes.

 

Her specific areas of research include:

  • Clinical outcomes and optimal management for women with ATM, CHEK2 and other moderate penetrance mutations in breast cancer susceptibility genes.
  • Uptake of endocrine prevention in patients with a history of chest wall radiation prior to age 30 or those with high risk lesions on breast biopsies, including atypical lobular hyperplasia (ALH), atypical ductal hyperplasia (ADH), and lobular carcinoma in situ (LCIS).
  • Breast oncology initiated mainstream genetic testing for women with newly diagnosed invasive breast cancer.

Recent Publications and References